ScienceDaily (Dec. 30, 2008) — The effectiveness of voriconazole in combating fungal infections has been confirmed by a new study to be featured in the International Journal of Antimicrobial Agents, published by Elsevier. Fungal infections can kill people with weakened immune systems, which can be caused by AIDS, cancer treatment or organ replacement, and the research reinforces earlier findings that this drug is a potent treatment for a wide range of these infections.

Voriconazole is an antifungal agent which has been approved for treatment of a broad range of fungal infections, including those caused by Candida species. The authors, from the United Kingdom, the United States of America and New Zealand, analyzed susceptibility data for the yeasts isolated from patients taking part in the voriconazole phase III clinical trials. The aim was to compare the effectiveness of voriconazole with other agents, by studying the yeasts' response to these antifungal agents in vitro, and also to check for resistance to voriconazole.

The researchers analyzed the effect of itraconazole, fluconazole, amphotericin B and voriconazole versus 1763 yeasts isolated from samples obtained from 472 patients. The yeast cultures obtained were predominantly Candida spp. (97.1%), although there were seven genera and 22 species of yeasts in all. The infections the patients were suffering from arose most commonly from surgery/trauma/burns (37% of patients), haematological malignancy (13%) or bacteria (11%).

The authors conclude that "Voriconazole exhibits high potency in vitro against a wide range of yeast species. It is notably more active than fluconazole in terms of both potency and spectrum, but shows similar activity to itraconazole against most yeasts." They also note that the activity of the agent in vitro may help predict the response of patients to treatment.

Story Source:

Adapted from materials provided by Elsevier, via EurekAlert!, a service of AAAS.

Journal Reference:

1. Johnson et al. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. International Journal of Antimicrobial Agents, 2008; 32 (6): 511 DOI: 10.1016/j.ijantimicag.2008.05.023

Related Stories

Gamma Interferon Could Aid Fight Against Fungal Infections (Nov. 3, 2007) — Interferon, the "superhero" cure for viral infections, may be a strong weapon in the battle against fungal infections in immunocompromised patients, according to a new article. Fungal infections ...  > read more

Scientists Develop Fungus-Fighting Vaccine (Sep. 5, 2005) — A group of scientists in Italy have developed a vaccine with the potential to protect against fungal pathogens that commonly infect humans, according to a study by Torosantucci and colleagues in the ...  > read more

Breast Cancer Drug Shows Promise Against Serious Infections (July 22, 2009) — An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born ...  > read more

Do Fungi Cause Retinopathies? (Mar. 17, 2008) — Researchers are studying fungi as a possible cause of strange retinopathies such as AZOOR. There are several retinopathies of unknown cause; among them AZOOR, Multifocal choroiditis, Serpiginous ...  > read more

Search ScienceDaily

Vaccine For Ear Infections